Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maribavir - Takeda

Drug Profile

Maribavir - Takeda

Alternative Names: 1263W94; Benzimidavir; Camvia; GW 1263; GW 1263W94; LIVTENCITY; LIVTENCITYTM; Maribavir - Shire; SHP-620; TAK 620; VP41263

Latest Information Update: 26 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Takeda; ViroPharma
  • Class Antivirals; Benzimidazoles; Ribonucleosides; Small molecules
  • Mechanism of Action Ganciclovir kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cytomegalovirus infections

Most Recent Events

  • 26 Dec 2023 Registered for Cytomegalovirus infections in China (PO)
  • 21 Dec 2023 Maribavir - Takeda receives Breakthrough Therapy status for Cytomegalovirus infections (Prevention) in China
  • 30 Nov 2023 Preregistration for Cytomegalovirus infections (In adolescents, In the elderly, In adults) in Japan (PO) (Takeda pipeline; February 2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top